GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

UK drugmaker’s new chief executive, Luke Miels, makes mark with deal for Boston-based biotech Nuvalent Business live – latest updates GSK’s new boss, Luke Miels, has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications. The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash. Continue reading...

Julia Kollewe · Tue, Jun 9, 2026, 4:17 AM
US news | The Guardian

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

UK drugmaker’s new chief executive, Luke Miels, makes mark with deal for Boston-based biotech Nuvalent

Business live – latest updates

GSK’s new boss, Luke Miels, has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications.

The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash.

This page shows an excerpt; reporting belongs to the original publisher. Some images or embeds may be omitted compared with the live article.